Caffeine/naproxen sodium - Bayer
Alternative Names: BAY-2880376Latest Information Update: 18 Feb 2026
At a glance
- Originator Bayer
- Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Xanthines
- Mechanism of Action Central nervous system stimulants; Cyclooxygenase inhibitors; Phosphoric diester hydrolase inhibitors; Purinergic P1 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 18 Feb 2026 No development reported - Phase-III for Postoperative pain (In adolescents, In the elderly, In volunteers, In adults) in USA (PO)
- 29 Jan 2024 Bayer completes a phase III trial in Postoperative pain (In adolescents, In the elderly, In adults, In volunteers) in USA (PO) (NCT05485805)
- 21 Sep 2022 Phase-III clinical trials in Postoperative pain (In adolescents, In the elderly, In adults, In volunteers) in USA (PO) (NCT05485805)